222610-47-1

Upstream product

• 871250-21-4 3-(4-benzyloxy-benzoylamino)-propionic methyl ester 
• 2345-34-8 4-acetyloxy-benzoic acid 
• 222610-36-8 N-(4-acetoxybenzoyl)-β-alanine methyl ester 

Downstream Products

• 871253-17-7 3-(4-{1-[4-(2,3,5,6-tetramethyl-benzyloxy)-phenyl]-propoxy}-benzoylamino)-propionic acid methyl ester 
• 871253-36-0 3-{4-[1-(2,6-dimethyl-4'-trifluoromethyl-biphenyl-4-yl)-3-methyl-butoxy]-benzoylamino }-propionic acid methyl ester 
• 871253-52-0 3-(4-[1-(4-bromo-3-methyl-phenyl)-5-methyl-hexyloxy]-benzoylamino)-propionic acid methyl ester 
• 871252-65-2 3-(4-{1-[4-(5-trifluoromethyl-pyridin-2-yl)-phenyl]-pentyloxy}-benzoylamino)-propionic acid methyl ester 
• 871251-15-9 (R,S)-3-(4-{(4-tert-butyl-phenyl)-[6-(4-trifluoromethyl-phenyl)-pyridin-3-yl]-methoxy}-benzoylamino)-propionic acid methyl ester 
• 871251-77-3 (R,S)-3-{4-[2-cyclohexyl-1-(4'-trifluoromethyl-biphenyl-4-yl)-ethoxy]-benzoylamino}-propionic acid methyl ester 
• 871250-60-1 3-{4-[6-(4-trifluoromethyl-phenyl)-pyridin-3-ylmethoxy]-benzoylamino}-propionic acid methyl ester 
• 871251-07-9 3-[4-(3-methyl-4'-trifluoromethyl-biphenyl-4-ylmethoxy)-benzoylamino]-propionic acid methyl ester 
• 222610-59-5 tris<4-<2-(methoxycarbonyl)ethylaminocarbonyl>phenyl> phosphite 

Relevant academic research and scientific papers

GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES

The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.

Serine peptidase modulators

The present invention relates to new compounds having modulatory (inhibitory and stimulatory) activity on serine peptidases and proteases in general and dipeptidyl peptidase IV, prolyl oligopeptidase (PO), dipeptidyl peptidase II (DPP II), fibroblast activation protein α (FAPα), lysosomal Pro—X carboxypeptidase and elastase in particular. These new compounds can be used for the treatment of a variety of disease states in which these peptidases are involved.

Structure-activity relationship of diaryl phosphonate esters as potent irreversible dipeptidyl peptidase IV inhibitors.

The previously reported diphenyl 1-(S)-prolylpyrrolidine-2(R, S)-phosphonate (5) was used as a lead compound for the development of potent and irreversible inhibitors of dipeptidyl peptidase IV (DPP IV, EC 3.4.14.5). The synthesis of a series of diaryl 1-